Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Astellas Venture Management
AddedFeb 13, 2024
UpdatedJun 28, 2026
Astellas Venture Management

Astellas Venture Management

Operating

California-based Astellas Venture Management: a leading biotechnology investment provider.

Location
Menlo Park, CA, US
Founded
2005
Firm
Compare
Portfolio
Employees
Website

Investments

Shinobi Therapeutics
Shinobi Therapeutics

Total Raised

$51M

Rounds

1

Series A$51MDecember 2023
Solu Therapeutics
Solu Therapeutics

Total Raised

$31M

Rounds

1

Seed$31MAugust 2023
Avilar Therapeutics
Avilar Therapeutics

Total Raised

$75M

Rounds

2

Seed$15MFebruary 2023
Casma Therapeutics
Casma Therapeutics

Total Raised

$154.9M

Rounds

4

Series C$46MNovember 2022
DEM Biopharma
DEM Biopharma

Total Raised

$70M

Rounds

1

Series A$70MJune 2022
Carbon Biosciences
Carbon Biosciences

Total Raised

$38M

Rounds

1

Series A$38MJune 2022
Orna Therapeutics
Orna Therapeutics

Total Raised

$321M

Rounds

3

Series A$80MFebruary 2021
Catamaran Bio
Catamaran Bio

Total Raised

$42M

Rounds

1

Series A$42MNovember 2020
TScan Therapeutics
TScan Therapeutics
Public

Total Raised

$197.5M

Rounds

6

Series B$35MJanuary 2020
Coda Biotherapeutics
Coda Biotherapeutics

Total Raised

$62.7M

Rounds

5

Series A$15MNovember 2019
Series A$19MSeptember 2018
Cleave Therapeutics
Cleave Therapeutics

Total Raised

$101M

Rounds

4

Series C$12MAugust 2019
Series B$37MAugust 2016
Series A$42MNovember 2011
Twentyeight-Seven Therapeutics
Twentyeight-Seven Therapeutics

Total Raised

$80M

Rounds

3

Series A$15MMay 2019
Series A$65MSeptember 2018
Redona Therapeutics
Redona Therapeutics

Total Raised

$66.8M

Rounds

3

Series UnknownJanuary 2019
Tizona Therapeutics
Tizona Therapeutics

Total Raised

$370M

Rounds

3

Series B$43MMarch 2016
Series A$27MJanuary 2016
Raze Therapeutics
Raze Therapeutics

Total Raised

$24M

Rounds

1

Series A$24MOctober 2014
DecImmune Therapeutics
DecImmune Therapeutics

Total Raised

$8.4M

Rounds

3

Series Unknown$2.3MFebruary 2013
Series Unknown$3.2MSeptember 2010
PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals
Public

Total Raised

$324.3M

Rounds

12

Series B$23MJune 2012
Verastem
Verastem
Public

Total Raised

$280M

Rounds

9

Series B$32MJuly 2011
PanOptica
PanOptica
Acquired

Total Raised

$109.9M

Rounds

5

Series A$30MJanuary 2011